Barrett Esophagus
A change in the lining of the lower esophagus from squamous to intestinal-type cells due to chronic acid reflux, carrying a risk of developing esophageal cancer.
Emergency Management: Acute food impaction due to a stricture or massive upper GI bleeding from a Barrett's ulcer requiring emergent endoscopy.
Barrett Esophagus is a premalignant condition in which the normal stratified squamous epithelium lining the distal esophagus is replaced by metaplastic columnar epithelium containing goblet cells (specialized intestinal metaplasia). This structural change occurs as an adaptive response to chronic mucosal injury from gastroesophageal reflux disease (GERD). The condition significantly increases the risk of developing esophageal adenocarcinoma.
Detailed Overview
Patients with Barrett esophagus are usually asymptomatic from the metaplasia itself, though they often report a long history of GERD symptoms such as heartburn and regurgitation. Diagnosis strictly requires both endoscopic visualization of columnar mucosa extending above the gastroesophageal junction and histologic confirmation of intestinal metaplasia. Management revolves around controlling reflux with high-dose proton pump inhibitors (PPIs) and performing periodic endoscopic surveillance with systematic biopsies to detect dysplasia. Depending on the grade of dysplasia, interventions range from continued surveillance to endoscopic ablative therapies or mucosal resection to prevent progression to cancer.
Epidemiology & Demographics
Prevalence is estimated at 1-2% of the general adult population, but up to 15% in patients with chronic GERD. It predominantly affects white males over the age of 50. The risk of progression to esophageal adenocarcinoma is approximately 0.2% to 0.5% per year for non-dysplastic Barrett's.
Etiological Mechanism
The primary etiology is chronic and severe gastroesophageal reflux, involving both gastric acid and duodenal bile salts, which causes repetitive mucosal injury.
Primary Causes
Chronic Gastroesophageal Reflux Disease (GERD). Weakness of the lower esophageal sphincter and the presence of a hiatal hernia severely exacerbate acid and bile exposure in the distal esophagus.
Chronic exposure to acidic gastric juice and basic biliary refluxate causes chronic esophagitis and ulceration of the native squamous epithelium. In the setting of ongoing inflammation, tissue repair mechanisms shift from regenerating squamous cells to differentiating into columnar cells that are more resistant to acid. Specifically, pluripotent stem cells in the esophageal basal layer or submucosal glands differentiate into specialized intestinal metaplasia featuring mucin-secreting goblet cells. While protective against acid, this metaplastic epithelium has unstable genomic integrity, predisposing it to sequential genetic mutations (e.g., TP53 loss) that drive progression from low-grade dysplasia to high-grade dysplasia and eventually adenocarcinoma.
Diagnostic Criteria & Guidelines
Diagnosis requires upper endoscopy (EGD) demonstrating 'salmon-colored' mucosa extending >= 1 cm proximal to the gastroesophageal junction, PLUS histological evidence of intestinal metaplasia (presence of goblet cells) on mucosal biopsy.
For Non-dysplastic Barrett's: Once-daily Proton Pump Inhibitor (PPI) therapy (e.g., Omeprazole 20-40 mg daily) to heal any concurrent esophagitis and control symptoms. Routine endoscopic surveillance every 3 to 5 years with Seattle protocol biopsies (4-quadrant biopsies every 2 cm).
Second-Line & Adjunctive Therapy
For Low-Grade Dysplasia: Endoscopic Eradication Therapy (EET), most commonly Radiofrequency Ablation (RFA), or intensive endoscopic surveillance every 6 months. For High-Grade Dysplasia: Endoscopic Mucosal Resection (EMR) for visible nodular lesions followed by RFA of the remaining flat Barrett segment. PPI therapy is often escalated to twice daily.
Surgical & Procedural Management
Anti-reflux surgery (e.g., Laparoscopic Nissen Fundoplication) may be considered for patients with refractory volume regurgitation. Esophagectomy is reserved for cases of high-grade dysplasia with multifocal progression to invasive adenocarcinoma that cannot be managed endoscopically.
Patient Counseling & Advice
Educate the patient that Barrett's is a precancerous condition, but the overall risk of developing cancer is low. Emphasize the critical importance of adherence to PPI therapy and compliance with scheduled endoscopic surveillance to catch any dysplastic changes early.
Follow-Up & Monitoring Schedule
Endoscopy with 4-quadrant biopsies. Frequency: Non-dysplastic (every 3-5 years). LGD (every 6 months or treat). Post-ablation (every 3-6 months for the first year, then annually).
Preventive Strategies
Aggressive management of GERD symptoms. Screening EGD is recommended for men with chronic GERD symptoms (>5 years) and two or more risk factors (age > 50, Caucasian, central obesity, current or past smoking, confirmed family history of Barrett's or esophageal adenocarcinoma).
For non-dysplastic Barrett's, the prognosis is excellent with routine surveillance. If high-grade dysplasia develops, successful eradication with endoscopic therapies is achieved in >80% of patients. Survival drastically drops if invasive adenocarcinoma develops.